Chronic Myeloproliferative Disorders Terminated Phase 2 Trials for Decitabine (DB01262)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00630994Low-Dose Decitabine in Treating Patients With Symptomatic MyelofibrosisTreatment